Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates

Robert Klamroth,1 Albrecht Gröner,2 and Toby L. Simon3

Pathogen safety is crucial for plasma-derived clotting factor concentrates used in the treatment of bleeding disorders. Plasma, the starting material for these products, is collected by plasmapheresis (source plasma) or derived from whole blood donations (recovered plasma). The primary measures regarding pathogen safety are selection of healthy donors donating in centers with appropriate epidemiologic data for the main blood-transmissible viruses, screening donations for the absence of relevant infectious blood-borne viruses, and release of plasma pools for further processing only if they are nonreactive for serologic markers and nucleic acids for these viruses. Despite this testing, pathogen inactivation and/or removal during the manufacturing process of plasma-derived clotting factor concentrates is required to ensure prevention of transmission of infectious agents. Historically, hepatitis viruses and human immunodeficiency virus have posed the greatest threat to patients receiving plasma-derived therapy for treatment of hemophilia or von Willebrand disease. Over the past 30 years, dedicated virus inactivation and removal steps have been integrated into factor concentrate production processes, essentially eliminating transmission of these viruses. Manufacturing steps used in the purification of factor concentrates have also proved to be successful in reducing potential prion infectivity. In this review, current techniques for inactivation and removal of pathogens from factor concentrates are discussed. Ideally, production processes should involve a combination of complementary steps for pathogen inactivation and/or removal to ensure product safety. Finally, potential batch-to-batch contamination is avoided by stringent cleaning and sanitization methods as part of the manufacturing process.

H

uman plasma is a source of clotting factor concentrates used for treatment of bleeding disorders caused by coagulation factor deficiencies. Such disorders include hemophilia A (Factor [F]VIII), hemophilia B (F IX), and von Willebrand disease (von Willebrand factor [VWF]); rarer disorders such as fibrinogen, FXIII, and FX deficiencies; and a number of acquired bleeding disorders. For von Willebrand disease, some rare bleeding disorders, and acquired bleeding, plasma-derived clotting factor concentrates, but not recombinant concentrates, are available. A four-factor prothrombin complex concentrate (Kcentra [Beriplex P/N in Europe], CSL Behring, Marburg, Germany) has been recently approved in the United States for reversal of warfarin.1

Efforts to prevent transmission of infectious agents were accelerated after the recognition of human immunodeficiency virus (HIV) transmission to hemophilia patients in 1983 and the identification of hepatitis C virus (HCV) thereafter. By the 1990s, there was substantial clinical evidence of a lack of transmission of lipid

ABBREVIATIONS: B19V = parvovirus B19; BVDV = bovine viral diarrhea virus; EMA = European Medicines Agency; HAV = hepatitis A virus; PARV4 = human parvovirus 4; PPV = porcine parvovirus; PRV = pseudorabies virus; QSEAL = Quality Standards of Excellence, Assurance, and Leadership; SINV = Sindbis virus; vCJD = variant Creutzfeldt-Jakob disease; WN = West Nile virus.

From the 1Center for Vascular Medicine, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Preclinical Research and Development, Pathogen Safety, CSL Behring, Marburg, Germany; and 3Plasma Research and Development/CSL Plasma, CSL Behring, King of Prussia, Pennsylvania.

Address reprint requests to: Toby L. Simon, MD, Plasma Research and Development/CSL Plasma, CSL Behring, 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406; e-mail: Toby.Simon@csblehring.com.

Funded by CSL Behring.

Received for publication June 6, 2013; revision received July 26, 2013, and accepted August 1, 2013.

doi: 10.1111/trf.12423

TRANSFUSION 2014;54:1406-1417.
membrane-enveloped viruses (hepatitis B [HBV], HCV, and HIV) using solvent/detergent (S/D) treatment. Nonenveloped viruses, including hepatitis A virus (HAV) and parvovirus B19 (B19V), presented additional challenges, as they are not inactivated by this technique. In Germany, pasteurization (heating at 60°C for 10 hours in a stabilized aqueous solution) was developed in the late 1970s for a clotting factor concentrate as a dedicated virus reduction method; this FVIII and VWF concentrate was licensed in 1981 and no proven cases of virus transmissions were reported.

More recently, prion transmission has become a concern. Manufacturing processes have evolved to include multiple steps to prevent transmission of both known and emerging blood-borne pathogens. The objective of this review is to examine current methods to prevent pathogen transmission via plasma-derived clotting factor concentrates by state-of-the-art selection of starting materials and their safety records are virtually identical. The manufacturing process of clotting factor concentrates from both derived products. These measures include selection of donors, screening of donations and fractionation pools are the first steps in product safety, followed by pathogen inactivation and/or removal (i.e., reduction) during manufacturing. Source plasma from apheresis commonly comes from compensated donors, while recovered plasma is from whole blood donors not compensated in cash. The manufacturing process of clotting factor concentrates from both starting materials and their safety records are virtually identical.

The European Medicines Agency (EMA) published a guideline focusing on the safety of plasma-derived products; the fourth version details measures necessary to prevent transmission of viruses to recipients of plasma-derived products. These measures include selection of donors, screening of donations and plasma pools for markers of infection with known viruses, and a manufacturing process with a high capacity to inactivate and/or remove viruses by selected steps validated for their virus reduction capacity. The guidelines state that "effective steps for the inactivation/removal of a wide range of viruses of diverse physicochemical characteristics" are required during manufacture. Both the EMA and the World Health Organization (WHO) recommend that two distinct steps with complementary modes of action be used, helping to ensure that any virus surviving Step 1 is inactivated and/or removed in Step 2. At least one step should inactivate or remove nonenveloped viruses. The EMA guideline further states that if a manufacturing process contains a step that reliably inactivates and/or removes a wide range of enveloped and nonenveloped viruses and additional manufacturing steps reliably contribute to inactivation and/or removal of viruses, the second step might not be required. In the United States, the manufacture of plasma-derived products must include at least one effective step for removal and/or inactivation of viruses. Further, careful validation is required for each inactivation or removal step. Various methods of virus inactivation and removal used in concentrates available in many countries are presented in Table 1.

To estimate the potential of specific steps for reducing prion infectivity, the EMA recommends evaluation studies for prions. Established processes for the production of clotting factor concentrates have been shown to reduce prion infectivity. Biologic products, including recombinant clotting factor products, are required to undergo complementary pathogen reduction steps analogous to those of plasma-derived clotting factor concentrates. Validation requirements are also similar for recombinant proteins. The safety focus in plasma-derived products has received greater attention because of the history of virus transmissions before 1990. However, the potential for virus contamination is an issue for all biologic products.

**PLASMA SCREENING**

Adherence to strict donor selection criteria and screening of donations effectively reduces the virus load to be inactivated and/or removed from the plasma pool for fractionation. Currently, no screening tests are able to detect prion infectivity in donors; although an experimental blood test for prion infection was recently developed. As a precaution, the EMA, the US Food and Drug Administration (FDA), and WHO recommend deferral of donors at risk of developing Creutzfeldt-Jakob disease (CJD) and its variant (vCJD) using a series of questions to exclude donations at risk from pooling and further processing.

Although screening for viral markers by serology and virus nucleic acid by nucleic acid testing (NAT) ensures that nearly all plasma units entering production are free of HBV, HCV, and HIV, inactivation and removal steps are necessary to reduce any viruses that may enter the plasma pool during a "window period" before markers can be detected. In 1999, it was estimated that this window for serologic testing could result in the identification of up to 1 in 10 plasma pools containing an HIV-infected unit and up to one in five containing an HBV- or HCV-infected unit. For a particular NAT assay and pool configuration, NAT has been shown to decrease the diagnostic window from 22 to 11 days for HIV-1, 59 to 34 days for HBV, and 82 to 23 days for HCV, thereby decreasing the amount of virus.
entering the plasma pool for fractionation. This reduces the residual risk by decreasing both the number of potentially infected units in the pool and the concentration of virus. However, screening does not sufficiently ensure the safety of products, as tests have limits of detection and are target specific. In addition, the size of the minipool for NAT impacts its effectiveness.

### INDUSTRY STANDARDS

The plasma industry developed two sets of standards through the Plasma Protein Therapeutics Association. The International Quality Plasma Program focuses on donor and center management. The second standard, known as Quality Standards of Excellence, Assurance, and Leadership (QSEAL), addresses manufacturing. Part of QSEAL is the inventory hold standard, which was introduced to address the “window period” described previously; this standard allows removal of previously donated units from donors who subsequently test positive for a virus (i.e., removal of window donations). This has been highly effective in reducing the risk of donations from infected donors who are nonreactive in serology (and NAT) at the time of donation from entering a manufacturing pool. The inventory hold is not a quarantine, as it would not interdict an infectious unit in the NAT window period if the donor did not return. The effectiveness of the hold is related to the large number of donors who donate frequently. All source plasma donations used for manufacturing are equivalent to donations for transfusion in terms of pathogen safety. In addition to manufacturing standards, QSEAL includes qualified donor and virus marker standards identical to those in the International Quality Plasma Program.

### VALIDATION STUDIES

Validation of production steps is necessary to estimate pathogen inactivation and/or removal capacity and provides confidence in the safety of a plasma-derived clotting factor product. The virus reduction capacity of a manufacturing process is tested in a dedicated laboratory using a validated scaled-down version of the manufacturing process by employing process intermediates spiked with high titers of an appropriate virus and then determining the virus reduction factor achieved. Viruses selected for validation should closely resemble those that pose the greatest threat of contamination, such as hepatitis viruses and HIV. For some viruses, no practical cell culture system is available; thus, specific model viruses are used. The selected viruses should include different genome, size, and envelope characteristics to represent the wide range of the physicochemical properties of viruses. This allows manufacturers to fully test the virus reduction capacity of the manufacturing process and to provide indirect

| Brand name (manufacturer) | Concentrated coagulation factor(s) | Virus inactivation and removal methods |
|---------------------------|-----------------------------------|---------------------------------------|
| Alphanate SD (Grifols)    | FVIII, VWF                        | Precipitation, Chromatography, Pasteurization, S/D, Lyophilization, Vapor heat |
| Biostate (CSL Ltd.)       | FVIII, VWF                        | Precipitation, Chromatography         |
| Humate-PH/Lytease-P (CSL Behring) | FVIII, VWF                        | Precipitation, Chromatography, Pasteurization, S/D, Lyophilization, Vapor heat |
| Xylegechase (CSL Behring) | FVIII, VWF                        | Pasteurization, S/D, Lyophilization   |
| Koate DVI (Talecris Biotherapeutics) | FVIII, VWF                        | Pasteurization, S/D, Lyophilization, Vapor heat |
| Wilate (Octapharma)      | FVIII, VWF                        | Pasteurization                        |
| Hemofil M (Baxter)       | FVIII                            | Pasteurization, S/D                   |
| Monoclate-P (CSL Behring) | FVIII                            | Pasteurization                        |
| Alphanine SD (Grifols)   | FVIII                            | Pasteurization                        |
| Bebulin VH (Baxter)      | FVIII                            | Pasteurization                        |
| Mononine (CSL Behring)   | FVIII                            | Pasteurization                        |
| Prothrombine P (CSL Behring) | FVIII                            | Pasteurization                        |
| Frenzolin P (CSL Behring) | FVIII                            | Pasteurization                        |
| Fibrinogen Lyophilization | FVIII                            | Pasteurization                        |
| Octaplex (Octapharma)    | FII, FVII, F IX, FX              | Precipitation, Chromatography         |
| Fibrinogen Octaplex (Octapharma) | FII, FVII, F IX, FX              | Precipitation, Chromatography         |

* Immunoaffinity chromatography. † Size-exclusion chromatography. ‡ Ion-exchange chromatography.
evidence that it reduces viruses in general. Reduction factors greater than 4 log are generally considered effective. Some virus reduction factors achieved by individual inactivation and/or removal steps are presented in Table 2.

Removal of prions from plasma-derived products is evaluated similarly to virus validation studies, based on a valid scaled-down version of the manufacturing process. For prion detection, the quantitative animal bioassay is considered most appropriate, although the in vitro methods of Western blot assay, enzyme-linked immunoabsorbent assay, and conformation-dependent immunoassay are also used for the detection of misfolded prion protein.

**PATHOGEN INACTIVATION METHODS**

**Pasteurization**

Pasteurization by heating the protein in aqueous stabilized solution at 60°C for 10 to 11 hours inactivates both lipid membrane–enveloped and a range of nonenveloped viruses (Table 3). Coagulation factors are heat sensitive; therefore, stabilizers (usually sugars, amino acids, or acetate) are added to preserve protein integrity and are removed after pathogen inactivation. Homogeneity of temperature throughout pasteurization must be validated by temperature mapping techniques. Studies on inactivation of HIV, HAV, and B19V by pasteurization in a FVIII/VWF concentrate have demonstrated virus reduction factors of at least 6.4, 4.2, and at least 3.9 log, respectively. Table 4 is an example of virus reduction factors observed in an actual product. Additional studies have demonstrated that pasteurization inactivates a wide range of enveloped and nonenveloped viruses, including bovine viral diarrhea virus (BVDV; a specific model virus for HCV), pseudorabies virus (PRV; a nonspecific model virus for HBV), herpes simplex virus-1, West Nile virus (WNV), and poliovirus.

**S/D treatment**

Lipid membranes of enveloped viruses are disrupted by S/D mixtures, thereby preventing binding to and infection of cells by these viruses. Organic solvents (e.g., tri(n-butyl)phosphate), combined with a nonionic detergent (polyethylene glycol octylphenyl ether [Triton X-100] or polysorbate 80), are typically used for treatment; S/D compounds are removed by chromatography or oil extraction. Product solutions are filtered to remove viruses entrapped in particles and thus protected from exposure to S/D. Homogeneous mixing and maintenance of a consistent temperature throughout incubation must be validated. Plasma Protein Therapeutics Association member companies have compiled data on effective virus inactivation by S/D treatment for FVIII, F IX, intravenous immunoglobulin, and intramuscular immunoglobulin. Virus inactivation was evaluated in 308 studies reflecting production conditions, as well as variables significantly beyond process specification; the results demonstrated

---

**TABLE 2. Virus reduction factors (log) for relevant viruses reported for individual process steps**

| Process step evaluated | Enveloped viruses | Non-enveloped viruses |
|------------------------|-------------------|-----------------------|
|                        | Virus reduction factors (log) |
|                        | HIV-HCV model, HBV model | HAV and model | B19V and model |
|                        | HIV-1 | BVDV | BHV | PRV | HAV | POL | B19V | PPV | CPV | MMV |
| Lyophilization17,45    | 1.2   | 1.7  | 1.3 | –   | 2.1 | 3.4 | –    | <1.0 | –   |
| Precipitation          |       |      |    |     |     |     |      |      |     |
| Cryoprecipitation32    | –     | –    | –   | 1.6 | 1.5 | –   | –    | 1.5  | –   |
| 3.5% PEG precipitation17 | <1.0 | <1.0 | <1.0 | –   | 3.3 | –   | 1.2  | –    | –   |
| Al(OH)3 adsorption/glycine precipitation/NaCl precipitation32    | 3.6   | 2.4  | –   | 3.7 | 2.4 | –   | 3.4  | –    | –   |
| S/D17,46              | ≥11.1 | ≥4.5 | ≥8.0 | ≥8.5 | NA | NA | NA  | NA  | NA  |
| Dry heat17,45,46       | 5.2†  | ≥4.9‡ | 2.1‡ | 4.9§ | ≥5.8‡ | ≥2.5‡ | 4.1§ | 4.1‡ | –   |
| Pasteurization17       | ≥6.4  | ≥8.9 | –   | 4.6 | 4.2 | –   | ≥3.9 | 1.1  | –   |
| Chromatography17       | ≥2.0  | <1.0 | 7.6 | –   | –   | <1.0 | –    | <1.0 | –   |
| Virus filtration15,47  | ≥6.4‡ | 6.6** | –   | >6.0§ | 6.8** | –   | –    | ≤1.0†† | –   |
| Vapor heat15,48        | >6.8  | >7.1 | >7.4 | >4.5 | ≥3.5†† | –   | –    | ≤1.0 | –   |

* Dashes indicate that no data are available.
† 100°C for 30 min.
‡ 80°C for 72 hr.
§ 100°C for 120 min.
|| In aqueous solution at 60°C for 10 hr.
¶ 35-nm filtration.
** 35- to 15-nm sequential filtration.
†† 60°C for 500 min, followed by 80°C for 60 min.

BHV = bovine herpes virus (a nonspecific model virus for HBV); CPV = canine parvovirus (a model virus for B19V); MMV = mice minute virus (a model virus for B19V); NA = not applicable; PEG = polyethylene glycol; POL = poliovirus Sabin type 2.
that product class, process temperature, protein concentration, and pH were not substantially involved in virus inactivation. In contrast, the concentration of S/D was critical when it was significantly below that specified for the process.\textsuperscript{52} For a FVIII and VWF concentrate, S/D treatment studies demonstrated reduction factors of more than 7.5 log for HIV, Sindbis virus (SINV), and PRV;\textsuperscript{46} for a F IX concentrate, reduction factors were greater than 4.5 log for HIV, SINV, vesicular stomatitis virus, BVDV, and PRV.\textsuperscript{17}

An important limitation of S/D treatment is specificity for lipid-enveloped viruses;\textsuperscript{4,53} there have been reports of patients with hemophilia with HAV or B19V infections after receiving S/D-treated FVIII concentrates.\textsuperscript{3,5,54-56}

### TABLE 3. Common methods for virus inactivation\textsuperscript{*}

| Treatment       | Treatment conditions                                                                 | Advantages                                                                                     | Limitations                                                                                              | Relevant properties to be recorded |
|-----------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------|
| Pasteurization  | Heat treatment in aqueous solution at 60°C for 10 hr                                     | Inactivates enveloped and some nonenveloped viruses, including HAV and B19V                     | Protein stabilizers may also stabilize viruses                                                           | Temperature                       |
|                 | Stabilizers (sugars, amino acids, or acetate) added                                     | Relatively simple equipment                                                                      | Stabilizers usually need to be removed after process is completed                                        | Temperature homogeneity            |
|                 |                                                                                       |                                                                                                | HBV is relatively heat stable                                                                           | Duration                          |
|                 |                                                                                       |                                                                                                | Process validation required                                                                             | Stabilizer concentration          |
|                 |                                                                                       |                                                                                                |                                                                                                           |                                  |
| Terminal dry heat| Heat treatment of lyophilized product at 80°C for 72 hr or Heat treatment of lyophilized product at 100°C for 30-120 min | Inactivates enveloped and some nonenveloped viruses, including HAV and B19V and Treatment applied on final container | At least 80°C usually required for reduction of hepatitis viruses                                      | Temperature                       |
|                 |                                                                                       |                                                                                                | Requires strict control of moisture content                                                            | Temperature homogeneity            |
|                 |                                                                                       |                                                                                                | Freezing and lyophilization and dry heat treatment conditions require extensive validation             | Duration                          |
|                 |                                                                                       |                                                                                                |                                                                                                           | Moisture content                  |
| Vapor heat      | Heat treatment of lyophilized product at 60°C for 10 hr, with water content adjusted to 7%-8% (wt/wt) or Additional heating at 80°C for 1 hr for some products | Inactivates enveloped and some nonenveloped viruses, including HAV and B19V and Treatment applied on final container | Freezing and lyophilization and heating conditions require extensive validation | Temperature                       |
|                 |                                                                                       |                                                                                                |                                                                                                           | Temperature homogeneity            |
|                 |                                                                                       |                                                                                                |                                                                                                           | Duration                          |
|                 |                                                                                       |                                                                                                |                                                                                                           | Moisture during heating           |
| S/D             | Typical conditions: 0.3% TNBP and 1% nonionic detergent, either Tween 80 (≥6 hr) or Triton X-100 (≥4 hr) at 24°C | Very efficient against enveloped viruses and Does not denature proteins and High process recovery and Relatively simple equipment and Not generally affected by buffers | Nonenveloped viruses unaffected and S/D reagents must be removed                                       | Temperature                       |
|                 |                                                                                       |                                                                                                |                                                                                                           | Duration                          |
|                 |                                                                                       |                                                                                                |                                                                                                           | Lipid levels must be controlled   |
|                 |                                                                                       |                                                                                                |                                                                                                           | In-process solution free from gross aggregates potentially protecting viruses |                                  |
|                 |                                                                                       |                                                                                                |                                                                                                           |                                  |

* Adapted from the World Health Organization.\textsuperscript{13}

TNBP = tri(n-butyl)phosphate.

### TABLE 4. Pathogen reduction factors for a pasteurized FVIII and VWF concentrate\textsuperscript{6,32}

| Treatment                        | Virus reduction factors (log) | Prion reduction factors (log) |
|----------------------------------|------------------------------|-------------------------------|
|                                  | HIV | BVDV | WNV | PRV | HAV | B19V | CPV | Microsomes | PrP\textsuperscript{Sc} |
| Cryoprecipitation (Stage 1)      |     | 1.6  |     |     |     | 1.9  |     | 3.5        | 3.9                       |
| Al(OH)\textsubscript{3}/glycine/NaCl (Stage 2) | 3.8 | 2.8  | 3.9 | 2.3 | 3.0 |     |     |            |                           |
| Pasteurization (Stage 3)         | ≥6.4| ≥8.9 | ≥7.8| 4.7 | 4.2 | ≥3.9 | 1.1 | 2.9        | 4.0                       |
| Lyophilization (Stage 6)         |     | 1.3  |     |     |     |     |     |            |                           |
| Overall reduction factor         | ≥10.2| ≥11.7| ≥7.8| 10.2| 7.8 | ≥3.9 | 6.0 | 6.4 | 7.9         |

* Reduction factor for the combined steps of pasteurization, second NaCl precipitation, dialysis, ultracentrifugation, and sterile filtration.

CPV = canine parvovirus (a model virus for B19V); PrP\textsuperscript{Sc} = disease-associated prion protein.
Therefore, a second virus reduction step is required in the manufacture of such plasma-derived products to close this gap in virus safety.

Dry heat treatment of lyophilized products

Most plasma-derived concentrates are lyophilized and, especially those treated with S/D, subsequently treated with dry heat to inactivate nonenveloped viruses that resist S/D treatment. Lyophilization confers a certain degree of virus inactivation; the moisture content of lyophilized products undergoing dry heat treatment should be kept low (typically <2%), as residual moisture may affect product stability, although higher levels may enhance inactivation of some viruses.

Dry heat treatment of lyophilized products has demonstrated favorable results for inactivation of relevant or model viruses of HAV, HBV, HCV, and HIV. The moisture content of lyophilized products undergoing dry heat treatment should be kept low (typically <2%), as residual moisture may affect product stability, although higher levels may enhance inactivation of some viruses.

Vapor heat

One drawback to lyophilization is that in addition to stabilizing coagulation factors, the removal of water can also stabilize potential viruses in the product. Adding water vapor to lyophilized products before heating, higher levels of virus inactivation can be achieved at equivalent temperatures. Vapor heating of lyophilized products targets enveloped and nonenveloped viruses and has demonstrated inactivation of hepatitis viruses and HIV. Lyophilization and vapor heat at 60°C inactivated approximately 6 log of HAV in spiked FVIII concentrates within 8 to 10 hours and similarly reduced HAV titers in F IX concentrates within 3 hours. Among 20 patients with hemophilia who received vapor-heated F IX infusions, none developed markers for infection with HCV or HIV during 6 to 15 months of follow-up, suggesting that vapor heat–treated concentrates may be associated with a low risk of viral infection. However, vapor heat at 60°C may be insufficient to inactivate HBV completely, depending on the virus load in the starting material (batch related) and the amount of product given to patients not vaccinated against HBV; there are reports of four hemophilia patients not vaccinated against HBV who became infected with HBV after receiving vapor-heated FVIII concentrate.

METHODS OF PATHOGEN REMOVAL

Partition processes: fractionation and chromatography

In addition to virus inactivation, viruses can also be physically removed from plasma-derived products by fractionation (precipitation or chromatography) and filtration (Table 5). Before the 1980s, plasma fractionation was mainly considered a step in protein purification; no dedicated virus reduction step (except for pasteurization of

| Treatment | Treatment conditions | Advantages | Limitations | Relevant properties |
|-----------|----------------------|------------|-------------|---------------------|
| Chromatography | • Ion exchange | • Purifies protein | • Virus removal highly dependent on choice of resin, protein solution, and buffers | • Resin packing |
| | • Size exclusion | • Can remove both enveloped and nonenveloped viruses, including HAV and B19V | • May be highly variable from one virus to another | • Protein elution profile |
| | • Antibody-mediated affinity chromatography | | • Degree of virus removal may change as resin ages | • Flow rate, contact time, and buffer volumes |
| | | | • Resin must be sanitized between lots | • Composition of buffer |
| | | | | • Number of cycles of resin use |
| Virus filtration | • Filters with pores of approximately 15, 20, 35, and 50 nm | • Does not denature or activate proteins when validated production conditions are used | • Degree of virus removal depends on the pore size of the filter | • Pressure |
| | | • High recovery of “smaller” proteins such as coagulation F IX | • Removal of small viruses may be incomplete | • Flow rate |
| | | | | • Filter integrity |
| | | | | • Protein concentration |
| | | | | • Ratio of product volume to filter surface area |
| | | | | • Buffer composition |

* Adapted from the World Health Organization.
TABLE 6. Virus reduction factors for a pasteurized FXIII concentrate utilizing ion-exchange chromatography and virus filtration

| Stages and Methods | Enveloped viruses | Nonenveloped viruses |
|--------------------|-------------------|----------------------|
|                    | HIV   | BVDV | WNv  | PRV  | HAV  | CPV  | B19V |
| Adsorption to Al(OH)₃/Vitacel and defibrination |      |      |      | 6.9  |      |      |      |
| Ion-exchange chromatography | 5.0  | 3.3  |      | 4.8  | 3.4  | 3.7  |      |
| Pasteurization (heat treatment at 60°C for 10 hr) | ≥7.7  | ≥8.1  | ≥7.4  | ≥8.0  | 4.3  | 1.0  | ≥4.0  |
| 20N/20N virus filtration | ≥6.1  | ≥5.0  | ≥7.4  | ≥6.4  | 2.6  | 1.0  | 6.1  |
| Overall virus reduction factor | ≥18.8 | ≥16.4 | ≥14.8 | ≥21.3 | ≥13.3 | 10.8 | NA |

CPV = canine parvovirus (a model virus for B19V); NA = not applicable; PRV = pseudorabies virus (a nonspecific model virus for HBV).

Virus filtration

Viruses may be removed from clotting factor concentrates via filtration employing retentive filters with pores smaller than the virus diameter (virus filtration, also called nanofiltration). Filtration may not be feasible for products containing proteins of a comparable or larger size to the viruses or pore size of the filter; thus, filtration is mainly limited to smaller-molecular-weight coagulation factors (e.g., F IX or FVIII). However, a VWF concentrate filtered through 35-nm pore membranes resulted in reduction factors of at least 5.0 log of enveloped viruses HIV, BVDV, and PRV, although filtration removed large VWF multimers as well. Filtration of a FVIII concentrate using 35- and 15-nm sequential filtration resulted in removal of enveloped (HIV, BVDV, and PRV) and nonenveloped (HAV and PPV) viruses. Virus filtration alone resulted in virus reduction factors of at least 3.6 log, while combination of S/D, chromatography, and virus filtration yielded reduction factors of at least 5.1 log for all tested viruses. Virus filtration of a FXIII concentrate using a 20-nm filter resulted in a reduction of enveloped (HIV, BVDV, PRV) and nonenveloped (HAV) viruses by at least 5.5 log and a reduction of a nonenveloped parvovirus by 3.4 log. Table 6 is an example of virus reduction achieved through the addition of a filtration step. In a safety study on F IX concentrate, a final virus filtration step was added following fractionation, chromatography, and S/D treatment. The 35- to 15-nm sequential filtration step resulted in a reduction factor of at least 6.8 log for HAV and at least 6.6 log for BVDV. Filtration of another F IX concentrate using two filters (20-nm mean pore size) in series very effectively removed enveloped and nonenveloped viruses.

RISK ASSESSMENT REGARDING VIRUS TRANSMISSION

An appropriate margin of safety with respect to bloodborne viruses is achieved when the overall virus reduction factor clearly exceeds the amount of virus potentially entering the manufacturing pool. In Europe, quantitative risk assessments are required. An estimate of virus particle content of the finished product is determined based on the worst case scenario of virus concentration in the starting material and the amount of plasma required to produce one vial, divided by the virus reduction factor.
demonstrated in validation studies. For this calculation, the following variables must be considered:\textsuperscript{10}

- Virus load in the plasma volume needed for production of one vial of product
  - Volume of manufacturing pool
  - Potential virus load in a donation from an infected donor remaining below the limit of detection of a NAT assay
  - Volume of donation
  - Number of viremic donations entering a manufacturing pool taking into account
    - Epidemiology in donor population
    - Inventory hold and look-back procedure
  - Virus doubling time, if more than one donation from an infected donor could enter the manufacturing pool
  - Product yield
- Virus reduction factors demonstrated in validation studies

A high margin of safety is documented when fewer than one virus particle per million doses is expected; this is based on the sterility assurance level with respect to bacteria, molds, and yeasts by pharmacopoeias worldwide. As viruses cannot replicate in a cell-free medium such as the dissolved final product, application of the sterility assurance level for viruses is conservative.

**PRION RISK REDUCTION**

Transmissible spongiform encephalopathies are a group of prion-associated, fatal neurodegenerative diseases. Three possible cases of prion transmission resulting in vCJD and one probable case of asymptomatic infection have been reported in patients in the United Kingdom who received non–leukoreduced red blood cells from asymptomatic infected individuals.\textsuperscript{73} To date, no recipients of pooled plasma-derived products have developed vCJD;\textsuperscript{39} however, there is one report of asymptomatic prion detection at autopsy in a hemophilia patient,\textsuperscript{74} probably due to prion-contaminated FVIII concentrate.\textsuperscript{74} As prion screening tests are currently unavailable, donor selection and manufacturing processes for prion removal are important.\textsuperscript{39} As requested by the WHO, EMA, and FDA, restrictions on plasma donation have been imposed in many countries.\textsuperscript{8-9,33} Plasma-derived proteins are leukoreduced by plasma preparation, decreasing the risk for prion transmission. Additionally, manufacturing steps for plasma fractionation and virus removal, including precipitation, chromatography, and filtration (Table 4), have also proven efficacy in evaluation studies.\textsuperscript{6,54,75} Inactivation of prions in plasma-derived clotting factor concentrates is not possible, as the needed techniques denature coagulation factors.\textsuperscript{33} Appropriate cleaning and sanitization methods for material and equipment used in the production of plasma-derived products inactivate and remove prion proteins; thus, batch-to-batch segregation can be achieved and batch-to-batch contamination excluded.\textsuperscript{76-79}

**EMERGING THREATS**

Emerging microbial pathogens or parasites are less of a threat because of sterile filtration, which, in combination with other steps before preparation of the finished product, removes these pathogens. However, “new emerging viruses” must be assessed very carefully with regard to potential impact on the safety of the plasma pool for fractionation and the final products. New emerging viruses may be novel, zoonotic viruses that are encountered as humans enter new geographic areas with previously undiscovered animal viruses that cross the species barrier to enter the human disease chain (e.g., HIV, yellow fever virus, severe acute respiratory syndrome coronavirus, Menangle virus, Hendra virus, Nipah virus, hantaviruses, monkeypox virus). Hepatitis E virus has been detected in different regions of the world and is considered a zoonosis; in particular, Genotype 3, mainly detected in domestic and wild pigs, has been found in humans in developed countries.\textsuperscript{80,82} Human parvovirus 4 (PARV4) and related parvoviruses have been identified in cows, pigs, primates, and humans.\textsuperscript{82-86} Furthermore, a “new” virus can emerge and/or reemerge in new geographic regions; for example, WNV was known in Africa and the Middle East but emerged in North America in 1999.\textsuperscript{87} Improved diagnostic methods have resulted in detection of previously unknown viruses (which should not be considered as emerging), such as B19V in 1975,\textsuperscript{88} HCV in 1989,\textsuperscript{89} human herpesvirus Type 8 in 1996,\textsuperscript{90} and TT virus in 1997.\textsuperscript{91} To meet this challenge, the epidemiology of emerging pathogens in the donor population and the potential infectious virus load in a donation during asymptomatic incubation must be addressed. Diligent surveillance of available information may result in a (temporal) deferral of donors based on geographic risk.

PARV4 can reach a high load in an infected person,\textsuperscript{92} but the prevalence of the virus is low in many regions.\textsuperscript{33,94} Contamination of plasma pools for fractionation with PARV4 has been reported,\textsuperscript{85} resulting in final products with PARV4 DNA. However, PARV4 DNA in current products is undetectable\textsuperscript{86} or lower than in products manufactured between 1970 and 1980,\textsuperscript{97,98} possibly because of thorough screening of donors and testing of donations for pathogens that may be associated with PARV4. Some manufacturing processes for coagulation factor concentrates remove and/or inactivate low levels of PARV4.\textsuperscript{98} Dedicated virus reduction steps in the manufacture of coagulation factor concentrates also reduced arthropod-transmitted viruses such as WNV,\textsuperscript{99} other flaviviruses (dengue virus),\textsuperscript{100} and togaviruses (Chikungunya virus).\textsuperscript{101}
reduction of these viruses during manufacture of clotting factor concentrates was also demonstrated using model viruses for validation. These data demonstrate that the measures currently taken are also relevant for emerging viruses.

**DISCUSSION AND CONCLUSIONS**

The combination of inactivation and removal methods, in addition to donation screening, has essentially eliminated transmission of viruses of principal concern, namely HAV, HBV, HCV, HIV, and B19V. As shown in validation studies, a strategy involving different steps for inactivation and removal is optimal for targeting viruses with different physicochemical properties. For instance, although S/D is highly effective against enveloped viruses, it is ineffective against nonenveloped viruses (e.g., HAV and B19V); thus, a second step, often dry heating of the lyophilized product, is implemented. Procedures for purification and concentration of the desired protein are usually less effective in virus removal than dedicated reduction steps, such as inactivation by heat and S/D treatment or removal by virus filtration. As diagnostic techniques advance, emerging pathogens may be identified, and their genomes may be detected in the final product (e.g., PARV4), depending on the manufacturing process. The methods employed make it extremely likely that any new pathogen would be inactivated or removed to a high degree, but diligence must be maintained.

Immune globulin and other plasma products, such as α1-proteinase inhibitor and C1 esterase inhibitor, are subject to similar pathogen reduction measures. In addition, low pH can be utilized for immune globulin products to inactivate certain viruses. Thus, the same high safety record has been observed with these products in recent years. Albumin has always been pasteurized to prevent pathogen transmission.

A product similar to fresh-frozen plasma (FFP), but pooled and treated with S/D, has been available in Europe and was recently licensed in the United States (Octaplas). Enveloped viruses are effectively inactivated by S/D treatment, and chromatographic methods reduce prion transmission potential. This product relies on testing of the donations for protection against nonenveloped virus, specifically HAV, B19V, and more recently, hepatitis E virus. Improved virus safety compared with FFP is based solely on the reductions observed with S/D methods for blood products.

Over the past 20 years, fears of potential infection and the introduction of recombinant factor products have fueled a shift toward recombinant products as the first choice for treatment of patients with hemophilia. However, opinions on the role of recombinant and plasma-derived concentrates for treatment vary. The United Kingdom Hemophilia Center Directors Organiza-

**REFERENCES**

1. Kcentra™ (Prothombin Complex Concentrate [Human]). Marburg, Germany: CSL Behring GmbH; 2013.
2. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999;39:1160-8.
3. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994;120:1-7.
4. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993;64:197-203.
5. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliaacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992;39:228-30.
6. Gröner A. Pathogen safety of plasma-derived products—Haemate-P/Humate-P. Haemophilia 2008;14(s5):54-71.
1. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. London, UK: EMA; 2010.

2. US Food and Drug Administration. Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. 2002. [cited 2013 Jan 25]. Available from: http://www.fda.gov/cber/guidelines.html

3. Farrugia A, Penrod J, Bult JM. Payment, compensation and replacement—the ethics and motivation of blood and plasma donation. Vox Sang 2010;99:202-11.

4. Simon TL. Monetary compensation for plasma donors: a record of safety. Transfusion 1998:38:883-6.

5. World Health Organization. Annex 4. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924. Geneva, Switzerland; 2004:150-224.

6. US Food and Drug Administration. Guide to inspections of viral clearance process for plasma derivatives. 2009. [cited 2013 Jan 25]. Available from: http://www.fda.gov/ICECI/Inspections/InspectionGuides/fda.gov/ICECI/Inspections/InspectionGuides/ucm074866.htm

7. Alphanate® (Antihemophilic Factor/von Willebrand Factor Complex [Human]). Los Angeles, CA: Grifols Biologicals, Inc.; 2007.

8. AlphaNine® SD (Coagulation Factor XI [Human]). Los Angeles, CA: Grifols Biologicals, Inc.; 2011.

9. Bebulin (Factor IX Complex). Westlake Village, CA: Baxter Healthcare Corporation; 2011.

10. Biostate® (Coagulation Factor VIII/von Willebrand Factor Complex [Human]). Broadmeadows, Australia: CSL Limited; 2010.

11. Hemofil M Antihemophilic Factor (Human). Glendale, CA: Baxter Healthcare Corporation; 2002.

12. Koate® -DVI Antihemophilic Factor (Human). Research Triangle Park, NC: Talecris Biotherapeutics, Inc.; 2006.

13. Monoclate-P® (Antihemophilic Factor [Human]). Kankakee, IL: CSL Behring; 2010.

14. Mononine® (Coagulation Factor IX [Human]). Kankakee, IL: CSL Behring; 2011.

15. Profilnine® SD (Factor IX Complex). Los Angeles, CA: Grifols Biologicals Inc.; 2011.

16. Wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]). Hoboken, NJ: Octapharma USA Inc.; 2009.

17. Corifact® (Factor XIII Concentrate [Human]). Kankakee, IL: CSL Behring LLC; 2011.

18. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010;8:149-54.

19. Gröner A. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. HaematoLOGICA 2007;92:846-9. HaematoLOGICA 2008;33:e24-6; author reply e27.

20. Beriplex® P/N (Human Prothrombin Complex). Ottawa, ON: CSL Behring Canada, Inc.; 2010.

21. Octaplex® (Human Prothrombin Complex). Vienna, Austria: Octapharma Pharmazeutika Produktionsges m.b.H.; 2010.

22. Humate-P® (Antihemophilic Factor/von Willebrand Factor Complex [Human]). Kankakee, IL: CSL Behring; 2012.

23. Burdick MD, Pfifat DY, Petteway SR Jr, et al. Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006;20:57-62.

24. Cai K, Gröner A, Dichtelmüller HO, et al. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion 2013;53:1894-905.

25. International Conference on Harmonization. Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Rockville, MD: US FDA; 1997.

26. European Medicines Agency. Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. London, UK: EMA; 1997.

27. Working Group “Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD).” Report of the Working Group “Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)”: statement on the development and implementation of test systems suitable for the screening of blood donors for vCJD—dated September 17, 2008. Transfus Med Hemother 2009;36:79-93.

28. Ironside JW. Variant Creutzfeldt-Jakob disease: an update. Folia Neuropathol 2012;50:50-6.

29. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009;144:14-23.
40. Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011;377(9764):487-93.
41. Plasma Protein Therapeutics Association. [cited 2013 Jan 25]. Available from: http://www.pptaglobal.org/
42. Whitaker BI, Schreiber GB, Simon TL. The residual risk of a window period (WP) unit entering a pool of source plasma. Transfusion 1998;38(Suppl):81S.
43. European Medicines Agency. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. London, UK: EMA; 1996.
44. Johnston A, Adcock W. The use of chromatography to manufacture purer and safer plasma products. Biotechnol Genet Eng Rev 2000;17:37-70.
45. Kim IS, Choi YW, Kang Y, et al. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. J Microbiol Biotechnol 2008;18:997-1003.
46. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006;34:281-8.
47. Johnston A, Macgregor A, Borovec S, et al. Inactivation and clearance of viruses during the manufacture of high purity factor IX. Biologicals 2000;28:129-36.
48. Berting A, Modrof J, Unger U, et al. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates. Transfusion 2008;48:1220-6.
49. European Medicines Agency. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. London, UK: EMA; 2004.
50. Vey M, Baron H, Weiner T, et al. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002;30:187-96.
51. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75-82.
52. Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009;49:1931-43.
53. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002;105:391-400.
54. Mannucci PM, Santagostino E, Di Bona E, et al. The outbreak of hepatitis A in Italian patients with hemophilia: facts and fancies. Vox Sang 1994;67(Suppl 1):31-5.
55. Chudy M, Budek I, Keller-Stanislawski B, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999;57:91-9.
56. Jee YM, Go U, Cheon D, et al. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol Infect 2006;134:87-93.
57. Saez A, Bosh N, Boadas N, et al. Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. Haemophilia 1999;5:260-5.
58. Smales CM, Pepper DS, James DC. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose. Biotechnol Bioeng 2002;77:37-48.
59. Unger U, Poelsler G, Modrof J, et al. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Transfusion 2009;49:1924-30.
60. Roberts PL, Dunkerley C, McAuley A, et al. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII. Vox Sang 2007;92:56-63.
61. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates. Lancet 1988;2(8615):814-6.
62. Arrighi S, Rossi R, Borri MG, et al. “In vitro” and in animal model studies on a double virus-inactivated factor VIII concentrate. Thromb Haemost 1995;74:868-73.
63. Blümel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002;42:1473-81.
64. Barrett PN, Meyer H, Wachtel I, et al. Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion 1997;37:215-20.
65. Shapiro A, Abe T, Aledort LM, et al. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of clotting factor concentrates. Transfusion 1995;35:24-37.
66. Mannucci PM, Zanetti AR, Colombo M. Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Br J Haematol 1998;98:427-30.
67. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37.
68. Lawrence JE. Affinity chromatography to remove viruses during preparation of plasma derivatives. Dev Biol Stand 1993;81:191-7.
69. Roberts PL, Walker CP, Feldman PA. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography. Vox Sang 1994;67(Suppl):69-71.
87. Mazurier C, Pouille M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004;86:100-4.
86. Chotourou S, Porte P, Nogre M, et al. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates. Vox Sang 2007;92:327-37.
85. Gröner A, Nowak T, Popp B, et al. High margin of pathogen safety of a plasma-derived FXIII concentrate. Haemophilia 2012;18(Suppl 3):31.
84. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2008;82(19):10289-96.
83. Adlhoch C, Kaiser M, Loewa A, et al. Diversity of parvovirus 4-like viruses in humans, chimpanzees, and monkeys in hunter-prey relationships. Emerg Infect Dis 2012;18:859-62.
82. Adlhoch C, Kaiser M, Ellerbrok H, et al. High prevalence of porcine Hokovirus in German wild boar populations. Virol J 2010;7:171.
81. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006;132:13-24.
80. Okamoto H. Genetic variability and evolution of hepatitis E virus. Virus Res 2007;127:216-28.
79. Friederich T, Bley C, Lohr K, et al. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion 2014;54:49-56.
78. Bauman PA, Lawrence LA, Biesert L, et al. Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 2006;91:34-40.
77. Gröner A, Boose JA. Evaluation of a cleaning procedure for its capacity to remove prions from equipment used in the production of plasma derivatives. Blood 2002;100(s):139b.
76. Flechsig E, Hegyi I, Enari M, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001;7:679-84.
75. Käsermann F, Kempf C. Sodium hydroxide renders the product protein PrPSc sensitive to proteinase K. J Gen Virol 2003;84(Pt 11):3173-6.
74. Vallerini D, Barozzi P, Quadrelli C, et al. Parvoviruses in the safety of plasma derivatives: verification of high safety standard for plasma-derived coagulation factor concentrates. Vox Sang 2012;103:413-8.
73. Ironside JW. Variant Creutzfeldt-Jakob disease. Br J Haematol 2006;91:34-40.
72. Gröner A, Nowak T, Popp B, et al. High margin of pathogen safety of a plasma-derived FXIII concentrate. Haemophilia 2012;18(Suppl 3):31.
71. Chotourou S, Porte P, Nogre M, et al. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates. Vox Sang 2007;92:327-37.
70. Mazurier C, Pouille M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004;86:100-4.
69. Cossart YE, Field AM, Cant B, et al. Parvovirus-like particles in human sera. Lancet 1975;1(7898):72-3.
68. Choong KL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62.
67. Moore PS, Gao SJ, Domínguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcoma. J Virol 1996;70:549-58.
66. Nishizawa T, Okamoto H, Konishi K, et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
65. Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012;52:1482-9.
64. Eis-Hubinger AM, Drexler JF, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. Transfusion 2010;50:266-7.
63. Vallerini D, Barozzi P, Quadrelli C, et al. Parvoviruses in blood donors and transplant patients, Italy. Emerg Infect Dis 2008;14:185-6.
62. Fryer JF, Kapoor A, Minor PD, et al. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006;12:151-4.
61. Modrow S, Wenzel JI, Schimanski S, et al. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang 2011;100:351-8.
60. Moshov E, Drezner J, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. Transfusion 2010;50:266-7.
59. Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2010;16:93:341-7.
58. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products. Transfusion 2001;41:978-86.
57. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
56. Xie YW, Chan PK, Szeto CK, et al. Clearance of dengue virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
55. Xie YW, Chan PK, Szeto CK, et al. Clearance of dengue virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
54. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
53. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
52. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
51. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
50. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.
49. Kreil TR, Berti A, Kistner O, et al. West Nile virus and the safety of plasma products: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-8.